145 related articles for article (PubMed ID: 3708878)
1. Naloxone provokes catecholamine release in phaeochromocytomas and paragangliomas.
Bouloux PM; Grossman A; Besser GM
Clin Endocrinol (Oxf); 1986 Mar; 24(3):319-25. PubMed ID: 3708878
[TBL] [Abstract][Full Text] [Related]
2. The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas.
Newbould EC; Ross GA; Dacie JE; Bouloux PM; Besser GM; Grossman A
Clin Endocrinol (Oxf); 1991 Jul; 35(1):55-9. PubMed ID: 1889139
[TBL] [Abstract][Full Text] [Related]
3. [Adrenal and extra-adrenal phaeochromocytoma: diagnostic features and localisation by determining plasma catecholamines (author's transl)].
Cordes U; Georgi M; Günther R; Beyer J
Dtsch Med Wochenschr; 1979 Mar; 104(9):317-23. PubMed ID: 761541
[TBL] [Abstract][Full Text] [Related]
4. Integrated concentrations of catecholamines in phaeochromocytoma.
Daggett P
Lancet; 1976 Oct; 2(7990):830-1. PubMed ID: 61501
[TBL] [Abstract][Full Text] [Related]
5. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion.
Geroula A; Deutschbein T; Langton K; Masjkur J; Pamporaki C; Peitzsch M; Fliedner S; Timmers HJLM; Bornstein SR; Beuschlein F; Stell A; Januszewicz A; Prejbisz A; Fassnacht M; Lenders JWM; Eisenhofer G
Eur J Endocrinol; 2019 Oct; 181(4):409-420. PubMed ID: 31370000
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors.
Procopiou M; Finney H; Akker SA; Chew SL; Drake WM; Burrin J; Grossman AB
Eur J Endocrinol; 2009 Jul; 161(1):131-40. PubMed ID: 19383804
[TBL] [Abstract][Full Text] [Related]
7. Biochemical diagnosis of pheochromocytoma and paraganglioma.
Lenders JW
Ann Endocrinol (Paris); 2009 Jun; 70(3):161-5. PubMed ID: 19296926
[No Abstract] [Full Text] [Related]
8. Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging.
Amar L; Eisenhofer G
Clin Endocrinol (Oxf); 2015 Sep; 83(3):298-302. PubMed ID: 25683095
[TBL] [Abstract][Full Text] [Related]
9. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management.
Foo SH; Chan SP; Ananda V; Rajasingam V
Singapore Med J; 2010 May; 51(5):e89-93. PubMed ID: 20593136
[TBL] [Abstract][Full Text] [Related]
10. Extra-adrenal phaeochromocytoma in a resource poor setting: A case report.
Emuze ME; Esan A; Adeleye J; Ifeh MO; Takure A; Akande T; Balogun W; Lawal AO
Endocr Regul; 2022 Feb; 56(1):48-54. PubMed ID: 35180819
[TBL] [Abstract][Full Text] [Related]
11. Increased sensitivity and accuracy of phaeochromocytoma diagnosis achieved by use of plasma-adrenaline estimations and a pentolinium-suppression test.
Brown MJ; Allison DJ; Jenner DA; Lewis PJ; Dollery CT
Lancet; 1981 Jan; 1(8213):174-7. PubMed ID: 6109856
[TBL] [Abstract][Full Text] [Related]
12. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors.
März J; Kurlbaum M; Roche-Lancaster O; Deutschbein T; Peitzsch M; Prehn C; Weismann D; Robledo M; Adamski J; Fassnacht M; Kunz M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():722656. PubMed ID: 34557163
[TBL] [Abstract][Full Text] [Related]
13. Gene targeting through o-methylated catecholamine metabolite patterns.
Shine B
Clin Chem; 2011 Mar; 57(3):361-2. PubMed ID: 21245368
[No Abstract] [Full Text] [Related]
14. Phaeochromocytoma in a 86-year-old patient presenting with reversible myocardial dysfunction.
Szwench E; P Czkowska M; Marczewski K; Klisiewicz A; Micha Owska I; Ciuba I; Januszewicz M; Prejbisz A; Hoffman P; Januszewicz A
Blood Press; 2011 Dec; 20(6):383-6. PubMed ID: 21675829
[TBL] [Abstract][Full Text] [Related]
15. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
Christensen TT; Frystyk J; Poulsen PL
Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
[TBL] [Abstract][Full Text] [Related]
16. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.
Bravo EL; Tarazi RC; Gifford RW; Stewart BH
N Engl J Med; 1979 Sep; 301(13):682-6. PubMed ID: 481462
[TBL] [Abstract][Full Text] [Related]
17. [Hereditary phaeochromocytoma in twins].
Tóth G; Patócs A; Tóth M
Orv Hetil; 2016 Aug; 157(33):1326-30. PubMed ID: 27523316
[TBL] [Abstract][Full Text] [Related]
18. Opioid modulation of normal and pathological human chromaffin tissue.
Mannelli M; Maggi M; DeFeo ML; Boscaro M; Opocher G; Mantero F; Baldi E; Giusti G
J Clin Endocrinol Metab; 1986 Mar; 62(3):577-82. PubMed ID: 3003144
[TBL] [Abstract][Full Text] [Related]
19. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.
Lamarre-Cliche M; Gimenez-Roqueplo AP; Billaud E; Baudin E; Luton JP; Plouin PF
Clin Endocrinol (Oxf); 2002 Nov; 57(5):629-34. PubMed ID: 12390337
[TBL] [Abstract][Full Text] [Related]
20. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
Eisenhofer G; Pacak K; Huynh TT; Qin N; Bratslavsky G; Linehan WM; Mannelli M; Friberg P; Grebe SK; Timmers HJ; Bornstein SR; Lenders JW
Endocr Relat Cancer; 2011 Feb; 18(1):97-111. PubMed ID: 21051559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
